Active ShortageTier 3 — Critical

UROMITEXAN

BAXTER CORPORATION

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of UROMITEXAN in Canada?

Yes. UROMITEXAN 100MG has an active shortage reported to Health Canada (last updated October 6, 2026).

Why is UROMITEXAN not available?

The reason the manufacturer reported: Demand increase for the drug.

When will UROMITEXAN be available again?

The estimated resolution date (October 31, 2026) has passed, but the report has not been updated yet. Follow this page to get an email when the status changes.

Can I still get this?Possibly — same-ingredient product records found

StatusActive Shortage

Same-ingredient products on file2 products

Affected strength100MG

Report last updated2026-10-06

Checked by MedShort2026-11-12

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Closest Matches

MESNA FOR INJECTION

FRESENIUS KABI CANADA LTD

100MG · DIN 02244931

Same strengthSame dosage formSame routeNo current shortage

Compare these two →

UROMITEXAN

BAXTER CORPORATION

100MG · DIN 02371839

Same strengthSame dosage formSame routeNo current shortage

Compare these two →

What this means

Does this mean my pharmacy is out of stock?

Not necessarily — a national shortage doesn't mean every pharmacy has run out. Some locations may still have stock, especially of a specific strength or pack size.

What should I do?

Health Canada classes this as a Tier 3 shortage, its highest-impact category. If you rely on this medication, talk to your pharmacist or care team now rather than waiting for your supply to run low. This product is usually given in a hospital or clinic, where the pharmacy team manages supply. If you're scheduled to receive it, ask your care team.

Estimated Resolution

2026-10-31

This is the manufacturer's estimated date, not a guarantee — actual resolution may come earlier or later.

Have you checked a pharmacy recently?

No community reports yet — be the first to share what you found.

Community reports are not verified by a pharmacy and may reflect a small sample size. This is not a guarantee of current stock.

DIN

02241411

Strength

100MG

Dosage Form

SOLUTION

Route

ORAL INTRAVENOUS

Active Ingredient

MESNA

Tier

Tier 3 — Critical

Last Updated

2026-10-06

Reason for Shortage

Demand increase for the drug.

Source

View original report on healthproductshortages.ca ↗

Past Reports for This Drug

UROMITEXAN has 2 shortage/discontinuation reports on file — this is one of them.

2026-10-27

Resolved

Demand increase for the drug.

Other Products from BAXTER CORPORATION

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

(20 MMOL/L) POTASSIUM CHLORIDE IN 3.3% DEXTROSE AND 0.3% SODIUM CHLORIDE INJECTION USP

DIN 00438014

(20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.9% SODIUM CHLORIDE INJECTION USP

DIN 00786292

(20 MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP

DIN 00438049

(20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP

DIN 00786209

(20MMOL/L) POTASSIUM CHLORIDE IN 5% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP

DIN 00437999

(40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP

DIN 00786217